LumiraDx Investor Presentation Deck
2
Coagulation
Diabetes
Inflammation
Respiratory
INR
D-Dimer
HbA1c
Creatinine
CRP
|Procalcitonin
COVID Ultra
COVID&Flu
Cardiovascular NT-proBNP
Troponin
Total GP Revenue
Total LumiraDx Revenue
1200
600
Builds Broad Testing Menu and
Volumes Per Customer
Illustrative YEAR 1
Volume Reimbursement (€)
600
120
1800
60
5.29
5.76
5.19
2.49
Illustration: Germany GP Office Group
Total GP and LumiraDx Revenue Per Year
21.71
Illustrative YEAR 2
Revenue (€) Volume Reimbursement (€)
600
120
1800
€ 3,171
€ 691
€ 9,338
€ 2,994
€ 1,303
€ 17,497
€ 10,180
1200
120
450
150
120
240
5.29
5.76
5.19
2.49
12.29
21.71
12.04
Revenue (€)
€ 3,171
€ 691
€ 9,338
Copyright © 2022 Lumirax Ltd. All Rights Reserved, Worldwide
€ 2,994
€ 1,474
€ 2,605
€ 2,889
€ 23,163
€ 11,070
Illustrative YEAR 2
Volume Reimbursement (€)
600
120
1800
480
1200
240
300
300
240
240
5.29
5.76
5.19
0.66
2.49
12.29
21.71
12.04
Revenue (€)
€ 3,171
€ 691
€ 9,338
€ 317
€ 2,994
€ 2,948
€ 5,211
€ 2,889
€ 27,559
€ 12,660
Note: Represents a disruptive pricing strategy to enable rapid adoption of multiple parameters on the instrument, with $20K revenue per instrument for the GP office in Year 1. Illustrative numbers
are not projections; they are goals and are forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the
control of the Company and its management and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be
material.
33
lumiraDx™View entire presentation